ArticleJournal of nanobiotechnology2025
CAT/SOD-Enriched Achyranthes bidentata nanovesicles mitigate TMJOA via ROS scavenging and JNK/FOXO1 pathway Inhibition.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Camouflage Protein-Engineered Extracellular Vesicles Alleviate TMJ-OA by Hijacking Caspase-1 to Suppress Pyroptosis.Journal of extracellular vesicles · 2026Article
- Downregulation of CD200 in the placenta of preeclampsia: a potential regulator of macrophage-mediated immune imbalance at the maternal-fetal interface.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Temporomandibular joint osteoarthritis (TMJOA) is an inflammatory disorder with limited treatment options. Given the key role of oxidative stress in TMJOA progression, targeting this pathway may offer therapeutic benefits. In this study, we isolated and characterized exosome-like nanovesicles from Achyranthes bidentata (ABNVs), a traditional Chinese herb known for its antioxidant properties. ABNVs exhibited an average size of 134.7 nm and a negatively charged surface (-30.32 mV), and were enriched with antioxidant enzymes such as catalase (CAT) and superoxide dismutase (SOD). In a rat TMJOA model, ABNVs (1 µg/mL) effectively reduced cartilage degradation, bone damage, and synovial inflammation while maintaining high biocompatibility. Immunohistochemical analysis revealed that ABNVs suppressed M1 macrophage polarization. In vitro, ABNVs did not impair chondrogenic differentiation but mitigated chondrocyte inflammation. Mechanistically, ABNVs scavenged reactive oxygen species (ROS) and reduced macrophage inflammation through CAT/SOD-mediated ROS clearance and modulation of the JNK/FOXO1 pathway. Additionally, ABNVs indirectly enhanced chondrogenic differentiation by inhibiting M1 macrophage activation. Our findings demonstrate that ABNVs hold promise as a therapeutic strategy for TMJOA by targeting oxidative stress and inflammation via ROS scavenging and JNK/FOXO1 regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.